Russell Investments Group Ltd. Reduces Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• Russell Investments Group Ltd. reduced its stake in IQVIA Holdings by 23.7% in the first quarter, now holding 99,005 shares valued at approximately $17.48 million.
• JPMorgan Chase & Co. significantly increased its investment in IQVIA by 45.7%, owning over 2.54 million shares worth around $448.69 million.
• IQVIA's quarterly earnings surpassed analysts' expectations, reporting $2.81 earnings per share on revenues of $4.02 billion, reflecting a 5.3% increase year-over-year.

Russell Investments Group Ltd. decreased its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 23.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 99,005 shares of the medical research company's stock after selling 30,836 shares during the period. Russell Investments Group Ltd. owned about 0.06% of IQVIA worth $17,480,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. American National Bank & Trust bought a new position in shares of IQVIA in the 1st quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in shares of IQVIA in the 1st quarter worth $33,000. Finally, ST Germain D J Co. Inc. increased its holdings in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IQV shares. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research note on Friday, May 23rd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the company from $260.00 to $160.00 in a research note on Friday, April 25th. UBS Group upped their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Trading Down 2.9%

NYSE IQV traded down $5.56 during trading on Thursday, hitting $186.48. The company had a trading volume of 560,941 shares, compared to its average volume of 1,963,761. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The company has a market cap of $31.70 billion, a price-to-earnings ratio of 27.00, a price-to-earnings-growth ratio of 2.11 and a beta of 1.30. The company's fifty day moving average is $172.49 and its 200-day moving average is $168.67.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.